Compile Data Set for Download or QSAR
Report error Found 2618 Enz. Inhib. hit(s) with Target = 'fMet-Leu-Phe receptor'
TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM631787(US20230348426, Example 57)
Affinity DataEC50:  0.0660nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM631879(US20230348426, Example 149)
Affinity DataEC50:  0.100nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620558(US20230303513, Example 9 | US20230303513, Example ...)
Affinity DataEC50:  0.100nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM631908(US20230348426, Example 178)
Affinity DataEC50:  0.100nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620563(US20230303513, Example 42 | US20230303513, Example...)
Affinity DataEC50:  0.100nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632027(US20230348426, Example 297)
Affinity DataEC50:  0.100nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632189(US20230348426, Example 459 | US20230348426, Exampl...)
Affinity DataEC50:  0.200nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632179(US20230348426, Example 449 | US20230348426, Exampl...)
Affinity DataEC50:  0.200nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632307(US20230348426, Example 577)
Affinity DataEC50:  0.200nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620567(US20230303513, Example 18 | US20230303513, Example...)
Affinity DataEC50:  0.200nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632417(US20230348426, Example 687)
Affinity DataEC50:  0.280nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632189(US20230348426, Example 459 | US20230348426, Exampl...)
Affinity DataEC50:  0.300nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620645(US20230303513, Example 87 | US20230303513, Example...)
Affinity DataEC50:  0.300nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620593(US20230303513, Example 53 | US20230303513, Example...)
Affinity DataEC50:  0.300nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620642(US20230303513, Example 84 | US20230303513, Example...)
Affinity DataEC50:  0.300nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM631838(US20230348426, Example 108)
Affinity DataEC50:  0.400nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620580(US20230303513, Example 21)
Affinity DataEC50:  0.400nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632044(US20230348426, Example 314)
Affinity DataEC50:  0.400nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632179(US20230348426, Example 449 | US20230348426, Exampl...)
Affinity DataEC50:  0.5nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620603(US20230303513, Example 55 | US20230303513, Example...)
Affinity DataEC50:  0.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632042(US20230348426, Example 312)
Affinity DataEC50:  0.5nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620562(US20230303513, Example 31 | US20230303513, Example...)
Affinity DataEC50:  0.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM631881(US20230348426, Example 151)
Affinity DataEC50:  0.5nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620560(US20230303513, Example 8)
Affinity DataEC50:  0.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620596(US20230303513, Example 41 | US20230303513, Example...)
Affinity DataEC50:  0.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454202(US10717708, Example 183 | US11186544, Example 183 ...)
Affinity DataEC50:  0.560nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2022
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454202(US10717708, Example 183 | US11186544, Example 183 ...)
Affinity DataEC50:  0.560nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454202(US10717708, Example 183 | US11186544, Example 183 ...)
Affinity DataEC50:  0.560nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50608807(CHEMBL5276622)
Affinity DataEC50:  0.580nMAssay Description:Agonist activity at FPR1 (unknown origin) expressed in CHO/Galpha16 cells assessed as increase in calcium flux by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/20/2024
Entry Details
PubMed
TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632069(US20230348426, Example 339)
Affinity DataEC50:  0.600nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620576(US20230303513, Example 20 | US20230303513, Example...)
Affinity DataEC50:  0.600nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632080(US20230348426, Example 350 | US20230348426, Exampl...)
Affinity DataEC50:  0.600nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM631913(US20230348426, Example 183)
Affinity DataEC50:  0.600nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632025(US20230348426, Example 295)
Affinity DataEC50:  0.600nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Mouse)
Queen Mary University of London

Curated by ChEMBL
LigandPNGBDBM50559829(CHEMBL4784510)
Affinity DataEC50:  0.600nMAssay Description:Agonist activity at mouse FPR1 expressed in CHO-A12 cells assessed as cAMP level incubated for 1.5 hr by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/20/2024
Entry Details
PubMed
TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632430(US20230348426, Example 700)
Affinity DataEC50:  0.670nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632413(US20230348426, Example 683 | US20230348426, Exampl...)
Affinity DataEC50:  0.700nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM631978(US20230348426, Example 248)
Affinity DataEC50:  0.700nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM631915(US20230348426, Example 185)
Affinity DataEC50:  0.700nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620559(US20230303513, Example 7)
Affinity DataEC50:  0.700nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM631862(US20230348426, Example 132)
Affinity DataEC50:  0.800nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620566(US20230303513, Example 19 | US20230303513, Example...)
Affinity DataEC50:  0.800nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632188(US20230348426, Example 458)
Affinity DataEC50:  0.800nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM631861(US20230348426, Example 131)
Affinity DataEC50:  0.800nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620564(US20230303513, Example 13 | US20230303513, Example...)
Affinity DataEC50:  0.800nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM631922(US20230348426, Example 192)
Affinity DataEC50:  0.800nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM632018(US20230348426, Example 288)
Affinity DataEC50:  0.800nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620640(US20230303513, Example 82 | US20230303513, Example...)
Affinity DataEC50:  0.800nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM631900(US20230348426, Example 170)
Affinity DataEC50:  0.900nMAssay Description: A mixture of forskolin (5 M final for FPR2 or 10 M final for FPR1) and IBMX (200 M final) were added to 384-well Proxiplates (Perkin-Elmer) pre-dott...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450320(US10676431, Example 83 | US11117861, Example 83)
Affinity DataEC50:  0.990nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2021
Entry Details
US Patent

Displayed 1 to 50 (of 2618 total ) | Next | Last >>
Jump to: